John Frith, DO
Internal Medicine · Farmington, MINPI 1679834097
Payments from drug & device makers
Across 669 payments — averaging $49.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$23K
- AstraZeneca$2K
- GSK$1K
- Takeda Pharmaceuticals U.S.A., Inc.$994
- Sanofi$845
- CSL Behring$670
- plus $4K from 31 others
What the payments were for
- Consulting fees$370%
- Speaking & faculty fees$18,29855%
- Travel & lodging$2,0366%
- Food & beverage$12,58238%
- Education$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 96 | $22,697 |
| AstraZeneca | 138 | $2,480 |
| GSK | 98 | $1,258 |
| Takeda Pharmaceuticals U.S.A., Inc. | 37 | $994 |
| Sanofi | 39 | $845 |
| CSL Behring | 38 | $670 |
| Alk-abello, Inc | 27 | $462 |
| Pfizer | 21 | $363 |
| Kaleo, Inc. | 19 | $356 |
| Genentech USA, Inc. | 21 | $324 |
| Teva Pharmaceuticals USA, Inc. | 19 | $320 |
| Pharming Healthcare, Inc. | 12 | $290 |
| Boehringer Ingelheim | 16 | $284 |
| Novartis | 15 | $272 |
| Octapharma USA, Inc. | 7 | $167 |
| Biocryst US Sales Co., LLC | 6 | $134 |
| Aimmune Therapeutics, Inc. | 5 | $104 |
| Grifols USA, LLC | 5 | $102 |
| Shire North American Group Inc | 5 | $91 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $91 |
| Blueprint Medicines Corporation | 3 | $84 |
| Sunovion Pharmaceuticals Inc. | 7 | $76 |
| Covis Pharma GmbH | 4 | $73 |
| Circassia Inc. | 5 | $66 |
| Phadia US Inc. | 3 | $53 |
| Amarin Pharma, Inc. | 1 | $51 |
| LEO Pharma Inc. | 2 | $38 |
| ADMA Biomanufacturing LLC | 3 | $37 |
| Organon | 2 | $35 |
| Optinose US, Inc. | 2 | $34 |
| Hospira, Inc. | 2 | $32 |
| Lilly USA, LLC | 1 | $25 |
| AbbVie | 1 | $21 |
| Greer Laboratories, Inc. | 1 | $21 |
| Amgen | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$20,916
How this compares
$32,992 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 18 | $51,348 |
| Dupixent SyringeDupilumab | 11 | $40,206 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $21,049 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $11,635 |
| Spiriva RespimatTiotropium Bromide | 14 | $10,928 |
| Ipratropium Bromide | 91 | $2,520 |
| Azelastine Hcl | 64 | $2,071 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $741 |
| Fluticasone Propionate | 16 | $689 |
| Montelukast Sodium | 32 | $332 |
| Hydroxyzine Hcl | 33 | $321 |
| Omeprazole | 14 | $157 |
| Prednisone | 13 | $119 |
| Triamcinolone Acetonide | 12 | $93 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $1,258 | $21,04918 claims |
| AstraZenecaBreztri Aerosphere | $2,480 | $11,63515 claims |
| Boehringer IngelheimSpiriva Respimat | $284 | $10,92814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Farmington
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
- Sudipto MukherjeeRoyal Oak$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.